- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02893137
Enhancing Optune Therapy With Targeted Craniectomy
Enhancing Optune Therapy of Recurrent Glioblastoma Multiforme Using Targeted Surgical Skull Remodeling
The present study proposes a new and potentially superior clinical approach to Optune™ therapy of selected glioblastoma patients. The approach is based on combining TTFields with targeted surgical skull remodeling, such as minor craniectomy or a distribution of burr holes, designed for the individual patient. Pre-clinical modeling results suggest that such procedures may enhance the induced electrical field strength by up to ~100% and thereby potentially improve the clinical outcome of treated patients to a significant extent.
The study is an open label phase 1 clinical pilot experiment designed to investigate feasibility, safety and efficacy of the concept. Fifteen patients with first recurrence of glioblastoma will be included in the trial. All patients will receive TTFields therapy with targeted craniotomy and best physician's choice chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Aarhus
-
Aarhus C, Aarhus, Denmark, 8000
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathological evidence of GBM using WHO classification criteria
- Estimated survival minimum three months
- Supratentorial tumor
- Not a candidate for further radiotherapy
- First disease recurrence in accordance with RANO criteria
- Karnofsky scale score minimum 70
- Ability to comply with Optune therapy
- Tumor characteristics which indicate significant expected benefit from feasible craniotomy or skull remodelling surgery combined with TTFields
- Focal tumor
- Most superficial border of tumor or resection cavity closer than 2 cm from brain surface
- Use of validated anti-conception for female participants in accordance with guidelines provided by the Danish Health and Medicines Authority
- Signed written consent form
Exclusion Criteria:
- Pregnancy or nursing. Fertile female participants will be required to take a validated pregnancy test for evaluation of pregnancy
- Less than four weeks since radiation therapy
- Infratentorial tumor
- Implanted pacemaker, programmable shunt, defibrillator, deep brain stimulator, other implanted devices in the brain, or documented clinically significant arrhythmias.
- Uncontrollable symptomatic epilepsy, refractory to standard medication. Epilepsy will not necessarily contraindicate participation in the trial as this is a common complication to the disease. Eligibility will be determined by the examining physician and investigators in conjunction upon careful consideration of patient safety.
- Contraindications for skull remodelling surgery, e.g. bleeding diathesis or severe infection.
- Significant co-morbidities (within four weeks prior to enrolment)
- Significant liver function impairment - ALT > 3 times the upper limit of normal
- Total bilirubin > upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL)
- Coagulopathy (as evidenced by PT or APTT > 1.5 times control in normal individuals not undergoing anticoagulation)
- Thrombocytopenia (platelet count < 100x10^3/μL )
- Anemia (Hb < 10 g/L)
- Active participation in another clinical treatment trial
Patients will be regarded as participants when they have signed a consent form and have been found suitable for enrolment by the examining physician, in accordance with the abovecriteria. Patients may receive medication depending on their clinical condition and other diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Craniectomy and Optune
Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery.
Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
|
For further information see www.optune.com
Other Names:
A small hole is placed in the skull between the tumor and the closest Optune electrode.
The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy.
Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of serious adverse events
Time Frame: Through study completion, an average of 18 months.
|
Based on CTCAE.
|
Through study completion, an average of 18 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Through study completion, an average of 18 months.
|
Through study completion, an average of 18 months.
|
|
Progression free survival
Time Frame: Through study completion, an average of 18 months.
|
Through study completion, an average of 18 months.
|
|
Progression free survival at six months
Time Frame: Through study completion, an average of 18 months.
|
Through study completion, an average of 18 months.
|
|
% 1-year survival
Time Frame: Through study completion, an average of 18 months.
|
Through study completion, an average of 18 months.
|
|
Objective response rate
Time Frame: Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Assessed by RANO criteria
|
Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Quality of life
Time Frame: Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Assessed by EORTC QLQ-30 and QLQ-BN20
|
Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Cumulative corticosteroid dosage
Time Frame: Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
|
Karnofsky performance score
Time Frame: Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Will be assessed at baseline and upon clinical follow-up every 3rd month until exclusion. Data will be presented at trial termination.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anders R Korshoej, MD, Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 54762
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Optune
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); NovoCure Ltd.; American Lebanese Syrian Associated...RecruitingMalignant Glioma | Ependymoma | Diffuse Intrinsic Pontine GliomaUnited States
-
Saint Luke's Health SystemNovoCure Ltd.WithdrawnCentral Nervous System Neoplasms, Primary
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterUniversity of Colorado, Denver; University of Miami; Columbia University; Cedars-Sinai... and other collaboratorsActive, not recruitingBrain CancerUnited States
-
Baylor Research InstituteTerminated
-
NovoCure GmbHActive, not recruitingGlioblastoma MultiformeUnited States, United Kingdom, Israel, Germany, Japan, Canada, France, Switzerland, Belgium, Czechia, Austria
-
University of Maryland, BaltimoreNovoCure Ltd.TerminatedBrain Tumor | RECURRENT GLIOBLASTOMAUnited States
-
Hackensack Meridian HealthNovoCure Ltd.Active, not recruiting
-
Sichuan UniversityRecruiting
-
Emory UniversityNational Cancer Institute (NCI)Recruiting